CT-FFR-guided Strategy for In-stent Restenosis
Study Details
Study Description
Brief Summary
This study will be a prospective, randomized clinical trial to compare standard practice guided by usual care testing to CT-FFR-guided management in patients with in-stent restenosis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This trial will randomize 294 patients with in-stent restenosis to receive either CT-FFR or routine clinical assessment. In all subjects, the investigators will review all diagnostic test results and determine a treatment strategy. The primary end point will be 12-month Major Adverse Coronary Event (MACE) rates, defined as all cause death, non-fatal myocardial infarction (MI), ischemia-driven target vessel revascularization (TVR). Secondary end points will include total medical costs, and quality of life (QOL), medical radiation exposure, etc. We will test noninferiority of current FFR-guided strategy compared with standard care strategy.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Usual Care Participants randomized to usual care will be evaluated according to institutional standard practice. The investigators will review clinical data and results of the diagnostic tests to recommend a treatment strategy, according to the institution's standard practice. |
Diagnostic Test: Usual Care
Participants randomized to usual care will be evaluated according to institutional standard practice.
|
| Experimental: CT-FFR Participants randomized to a CT-FFR strategy will be assigned to non-invasive CT-FFR evaluation. The investigators will review the results CT-FFR, and will recommend a further ICA test if CT-FFR≤0.8. The investigators will review the results of all available diagnostic tests, including CT-FFR and ICA, and will recommend a treatment strategy accordingly. |
Diagnostic Test: CT-FFR
CT-FFR is a type of non-invasive procedure to provide a 3D model of coronary arteries as a way to evaluate the hemodynamic significance of coronary artery lesions. CT-FFR calculates FFR from subject-specific CCTA data using computational fluid dynamics technology. CT-FFR value ≤0.80 is considered hemodynamically significant.
|
Outcome Measures
Primary Outcome Measures
- 12-month MACE [12 months]
12-month Major Adverse Coronary Event (MACE) rates, defined as: All cause death Non-fatal myocardial infarction (MI) Ischemia-driven target vessel revascularization (TVR)
Secondary Outcome Measures
- MACE [3-month, 6-month, 24-month, 36-month]
MACE defined as: All cause death Non-fatal MI Clinical-driven TVR
- Rates of Target lesion failure (TLF) [3-month, 6-month, 24-month, 36-month]
Composite of clinically driven TLR, MI or cardiac death related to the target vessel.
- Total costs [6-month, 12-month]
Total costs will be calculated from the use of all cardiac-related invasive and non-invasive tests, revascularization procedures, hospital admissions and outpatient attendances due to a cardiovascular cause, and cardiac medications.
- Quality of life (QOL) will be assessed using the EQ-5D-VAS questionnaire [6-month, 12-month]
Quality of life (QOL), will be assessed using the EQ-5D-VAS questionnaire
- Seattle Angina Questionnaire [6-month, 12-month]
angina status, will be assessed using the Seattle Angina Questionnaire
- Cumulative radiation exposure [6-month, 12-month]
Cumulative radiation exposure within 6-month and 12-month of study entry included all cardiovascular tests and invasive procedures, including CTA, myocardial perfusion imaging, and ICA.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
(1) >18 years old;
-
(2) ability to provide informed consent;
-
(3) previous PCI who underwent CCTA and have at least 1 lesion with a percent diameter in-stent stenosis between 30% and 90% in a coronary artery with a ≥2.25 mm reference vessel diameter by visual assessment;
-
(4) accepted further clinically indicated coronary testing, coronary arteriography, or FFR, or IVUS, or PCI, etc.
Exclusion Criteria:
-
(1) Prior coronary artery bypass surgery (CABG), heart valve surgery, cardiac pacemaker, or implanted cardiac defibrillator;
-
(2) Target vascular stents were evaluated for implantation within one month;
-
(3) unstable clinical conditions including acute chest pain, cardiogenic shock, congestive heart failure (NYHA grade III or IV), unstable blood pressure (systolic blood pressure < 90mmHg) or acute pulmonary edema;
-
(4) Acute myocardial infarction occurred within 7 days before enrollment, and left ventricular ejection fraction ≤40%;
-
(5) Other severe cases are not suitable for clinical trials including complex congenital heart disease, sick sinus syndrome, long QT syndrome, severe arrhythmia, tachycardia, severe asthma, severe or very severe chronic obstructive pulmonary disease (COPD) and severe chronic renal damage;
-
(6) Contraindication to beta blockers, nitroglycerin, adenosine, or allergy to iodine contrast agents;
-
(7) Pregnancy or pregnancy status unknown;
-
(8) Life expectancy <1 years;
-
(9)Repeated enrollment;
-
(10) Any other factors that other researchers consider not suitable for inclusion or completion of this study.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Yan'an Affiliated Hospital of Kunming Medical University
Investigators
- Principal Investigator: Qiang Xue, Yan'an Affiliated Hospital of Kunming Medical University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- In-stent Restenosis